Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Individual analysis of patients with HoFH participating in a phase 3 trial with lomitapide: The Italian cohort.

Nutrition, metabolism, and cardiovascular diseases : NMCD - 1 Jan 2016

Averna M, Cefalù A B, Stefanutti C, Di Giacomo S, Sirtori C R, Vigna G

Abstract excerpt

BACKGROUND AND AIMS: The efficacy and safety of lomitapide as adjunct treatment for adults with homozygous familial hypercholesterolaemia (HoFH) have been confirmed in a phase 3 trial. Given the small number of patients (N = 29), and variations in patient characteristics, examining individual cases provides additional details regarding patient management with lomitapide. Here, we examine the details of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticholesteremic Agents
Share to Benzimidazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers

Share to Cholesterol, LDL

Share to Hyperlipoproteinemia Type II

Share to Receptors, LDL

Share to Treatment Outcome

Source

Identifiers

PMID: 26723464
DOI: 10.1016/j.numecd.2015.11.001

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Individual analysis of patients with HoFH participating in a phase 3 trial with lomitapide: The Italian cohort.PMID 26723464Read ↗

Lomitapide for the treatment of hypercholesterolemia.Semantic proximity Read ↗

Lomitapide for the management of homozygous familial hypercholesterolemia.Semantic proximity Read ↗

The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia - a post-hoc analysis of a Phase 3, single-arm, open-label trial.Semantic proximity Read ↗

Contemporary lipid-lowering management and risk of cardiovascular events in homozygous familial hypercholesterolaemia: insights from the Italian LIPIGEN Registry.Semantic proximity Read ↗

Lomitapide: A Medication Use Evaluation & a Formulary PerspectiveSemantic proximity Read ↗

MTTP gene variants and lomitapide response in a cohort of patients with homozygous familial hypercholesterolemiaSemantic proximity Read ↗

Balancing Low-density Lipoprotein Cholesterol Reduction and Hepatotoxicity With Lomitapide Mesylate and Mipomersen in Patients With Homozygous Familial Hypercholesterolemia.Semantic proximity Read ↗

Management of homozygous familial hypercholesterolaemia in two brothers.Semantic proximity Read ↗

Mipomersen and lomitapide: Two new drugs for the treatment of homozygous familial hypercholesterolemia.Semantic proximity Read ↗

MTP Gene Variants and Response to Lomitapide in Patients with Homozygous Familial Hypercholesterolemia.Semantic proximity Read ↗

Evidence for improved survival with treatment of homozygous familial hypercholesterolemiaSemantic proximity Read ↗

Use of microsomal triglyceride transfer protein inhibitors in patients with homozygous familial hypercholesterolemia: translating clinical trial experience into clinical practice.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.